Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Orthopedics Neurology

Pozen gains after positive PIII results for ulcer reducing aspirin, as partner search gains momentum

This article was originally published in Scrip

Executive Summary

Pozen saw its share price surge as much as 19% in early trading on 22 March before closing up 8.8%, or $0.42, to $5.22 after reporting positive top-line data from its Phase III pivotal trials for its novel gastrointestinal-friendly aspirin candidate PA32540. The news added $11.6 million to the company's value at $143.6 million. The company is developing PA32540 for the secondary prevention of cardiovascular disease in patients that are at risk for aspirin-associated GI complications.

Table

View full table

Topics

Related Companies

Tags:
Orthopedics Neurology
Latest Headlines

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

NASDAQ Is Nice But Home Provides Comfort For Europe’s Biotechs

Amgen Planning Pivotal Obesity Program For MariTide

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

See All
UsernamePublicRestriction

Register

SC016720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By